AWA Point
Danish outerwear brand Rains wins court battle against Zara
By AWA | Posted on May 28, 2020
This case concerns whether three raincoats produced and marketed by Zara infringed on two raincoats from Rains, the Long Jacket and Parka Coat, under the Danish Copyright Act and the Danish Marketing Act. The Danish Maritime and Commercial Court handed down its judgement on May 15, 2020 between Rains Aps and Zara Denmark A/S and...
Tags: copyright, designs, marketing, Rains, Zara
Maintaining Traction in Commercial IP Strategy and Daily IP Operations
By AWA | Posted on May 22, 2020
The business environment is changing and the impacts can be felt in the commercial role and management of intellectual property. Head of AWA Strategy, Henrik Olsson will address these changes from a point of view of how companies are being affected in terms of intellectual property management. Companies will need to adapt internal and external...
Filed under: Webinars
Tags: business, commercial, IPR, strategy
Faster and Stronger Protection for New Technologies in China
By AWA | Posted on May 22, 2020
There have been a series of amendments to China’s Patent Examination Guidelines over the past year, especially regarding the examination of applications for technologies concerning the internet, AI, big data, block chain and business methods. Unclear issues have been clarified and examination standards unified. Join Xiaofan Chen from AWA Asia’s Beijing office who will discuss...
Tags: AI, big data, block chain, business methods, china, examination guidelines, Internet, patents
Valuation for Technology & IP Transactions in Good Times & Bad
By Thomas Ewing | Posted on May 22, 2020
Transactions involving new technologies and their related intangible assets have grown steadily. Restarting the world’s economic engines after the Coronavirus-induced shutdown suggests that such transactions may increase rapidly as firms seek to gain immediate value from their non-core assets. This webinar provides a context for valuation and discusses its role in commercial transactions (investment, M&A,...
Tags: IPR, licensing, patents, strategy, transactions, valuation
Intellectual Property and Domains for Start-ups and Scaleups
By Joacim Lydén, Kristian Martinsson | Posted on May 22, 2020
Explores the essentials when it comes to IP and domain names for start-ups and scaleups. An expert panel focuses on practical advice and business tools available in terms of branding and trademarks, innovations and patents as well as digital assets like domain names. Hosted by value creation specialist Cathrin Johansson with expert panellists Kristian Martinsson and...
Tags: domains, inventions, IPR, patents, scaleups, startups, trademarks
China becomes top international patent filer
By AWA | Posted on May 20, 2020
China filed 58,990 applications through WIPO’s Patent Cooperation Treaty (PCT) System last year, ending the US’s stronghold on the top position since the PCT began operations in 1978 by 1,150 applications. The numbers echo a sophisticated and coordinated effort to advance innovation and realise a high-value economy from the Chinese government. This is especially true considering in 1999,...
Tags: BOE, china, Huawei, IPR, Oppo, patents, PCT, Ping An, SPC
Punitive damages case appears in list of top 10 IP cases from China’s Supreme People’s Court
By Ai-Leen Lim | Posted on May 20, 2020
On April 21, 2020, China’s Supreme People’s Court released a list of the top 10 intellectual property law cases of 2019. The cases cover patent (invention and design), trademark, copyright and unfair competition. One of the cases selected involved a US Pilates company where punitive damages were awarded. While punitive damages are well-established in terms...
Filed under: Insights
Tags: Balanced Body, Infringement, IPR, punitive damages, SPC, statutory damages, trademarks, Yongkang Elina
Clarifying the patentability of medical use inventions in China
By AWA | Posted on May 20, 2020
At the end of 2019, the new Coronavirus (2019-nCoV) emerged. It has gone on to infect millions of people worldwide and so far, claimed the lives of over a quarter of a million people. COVID-19 has disrupted the world economy like never before. At the same time, it has brought unprecedented global attention to disease...
Tags: china, CNIPA, EPO, Gilead, inventions, JPO, medical use, patents, Remdesivir
EPO rules plants and animals exclusively obtained by essentially biological processes not patentable
By AWA | Posted on May 18, 2020
It has been clear that essentially biological processes for the production of plants or animals are explicitly excluded from patentability under Article 53(b) EPC. However, patentability of products of the essentially biological processes, such as plants and animals, has been questioned and repeatedly visited by the Enlarged Board of Appeal in recent years. On 14...
Filed under: Insights
Tags: animals, biological, Board of Appeal, EPO, interpretation, patents, plants
What patent protection does Gilead’s COVID-19 treatment Remdesivir have?
By Anders Heebøll-Nielsen, Michael Bech Sommer | Posted on April 30, 2020
On 29 April 2020 Gilead announced that its drug Remdesivir has a positive effect in the treatment of COVID-19 from a phase three trial of the drug. The investigation was so successful that for ethical reasons it was “unblinded” – the effect observed was so significant that retaining the group on placebo would prevent those...
Filed under: Insights
Tags: applications, Coronavirus, COVID-19, Gilead, IPR protection, patents, PCT, Remdesivir
Recent contributors
Partner, Attorney at Law, Business Area Manager
Associate, Attorney at Law, European Trademark and Design Attorney
Senior Associate, Patents
Partner, European Patent Attorney, Authorised Swedish Patent Attorney, UPC Representative
Partner, Attorney at Law, Group Vice President
Senior Associate, Attorney at Law